Table II.
Benefits of Treating Hypertension in Older Persons
| End‐Point Reduction Compared With Placebo (%) | ||||
|---|---|---|---|---|
| Trial Patient Ages in Years (Entry BP) | Stroke | HF | CHD | All CVD |
| SHEP ≥60 (mean 72) (170/77 mm Hg) | 36* | — | 27 | 32 |
| STOP‐Hypertension 70–84 (195/102 mm Hg) | 47* | 51* | 13* | 40* |
| MRC 65–74 (160–209/≤114 mm Hg) | 25* | — | 19 | 17* |
| Syst‐Eur ≥60 (mean 70) 174/86 mm Hg | 42* | 29 | 30 (MI) | 31* |
| BP=blood pressure; HF=heart failure; CHD=coronary heart disease; CVD=cardiovascular disease; MI=myocardial infarction; SHEP=Systolic Hypertension in the Elderly Program study; STOP‐Hypertension=Swedish Trial in Old Patients with Hypertension study; MRC=Medical Research Council trial; Syst‐Eur=Systolic Hypertension in Europe study; *statistically significant | ||||